LOXO-195 is a potent and selective TRK inhibitor designed to overcome acquired resistance that may emerge in patients receiving larotrectinib (LOXO-101) or multikinase inhibitors with anti-TRK activity.
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors. [1]
Reference:
[1] A.Drilon, et al, Cancer Discov., 2017, 7(9), pp 963-972.
Signal Word
Hazard Statements
Precautionary Statements
HS Code
RIDADR
RETCS
Legal Information
Not classified as a hazardous substance or mixture
2934990300
NONH for all modes of transport
Sales limitations may apply.
1. Product Specification
2. Safety Data Sheet
Please inquire for pricing and availability of this product by writing email tosales@kumidas.com.
